Centralised Biological Therapy Registry for Moderate to Severe Plaque Psoriasis – Overview and Methodology

1. Braun-Falco O, Plewig G, Wolff H. Dermatológia a venerológia. Martin: Osveta; 2001.10.1007/978-3-642-97931-6Search in Google Scholar

2. Stern R. A promising step forward in psoriasis therapy. JAMA 2003; 290, 3133-5.10.1001/jama.290.23.313314679277Search in Google Scholar

3. PSONET.eu [Internet], Italy: European surveillance network to monitor the long term effectiveness and safety of systemic agents in the treatment of psoriasis; [updated 2013; cited 2014 Feb 3]. Draft protocol 20 7. Available from: http://www.psonet.eu/cms/.Search in Google Scholar

4. Driessen R, Boezeman J, Van de Kerkhof P, De Jong E. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009, 160 (3): 670-5.10.1111/j.1365-2133.2008.09019.x19210502Search in Google Scholar

5. Van Lumig P, Driessen R, Berends M, Boezeman J, Van de Kerkhof P, De Jong E. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol 2013; 26 (3): 283-91.10.1111/j.1468-3083.2011.04044.x21435026Search in Google Scholar

6. Oosteveen A, De Jong E, Evers A, Donders A, Van de Kerkhof P, Seyger M. Reliability, Responsiveness and Validity of Scalpdex in Children with Scalp Psoriasis: The Dutch Study. Acta Derm Venereol 2014; 94 (2): 198-202.10.2340/00015555-162224002532Search in Google Scholar

7. Nijsten T, Wakkee M. Psocare: Italy Shows the Way in Postmarketing Studies. Dermatology 2008; 217: 362-4.10.1159/00015659818810240Search in Google Scholar

8. Naldi L, Cazzaniga S. Dermatology: experience with the disease registry for the treatment of psoriasis. Recenti Prog Med 2013; 104 (6): 236-40.Search in Google Scholar

9. Schmitt-Egenolf M. PsoReg – The Swedish Registry for Systemic Psoriasis Treatment. Dermatology 2007; 214: 112-17.10.1159/00009856817341858Search in Google Scholar

10. Hägg D, Eriksson M, Sundstrom A, Schmitt-Egenolf M. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS ONE 2013; 8(5): e63619. doi:10.1371/journal.pone.0063619.10.1371/journal.pone.0063619365514623691076Search in Google Scholar

11. Gniadecki R, Kragballe K, Dam T, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. BJD 2011; 164: 1091-6.10.1111/j.1365-2133.2011.10213.x21219290Search in Google Scholar

12. Burden A, Warren R, Kleyn C, McElhone K, Smith C, Reynolds N, Ormerod A, Griffiths C. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives. British Journal of Dermatology 2012; 166: 545-54.10.1111/j.1365-2133.2012.10835.x22356636Search in Google Scholar

13. Rivera R, Garcia-Doval I, Carretero G, Daudén E, Sánchez-Carazo J, Ferrándiz C, Harrera E, Alsina M, Ferrán M, López-Estebaranz J, Goméz F, Herranz J, Carrascosa J, Vanaclocha F. BIOBADADERM, the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology: First Report. Actas Dermosifiliogr 2011; 102 (2): 132-41.10.1016/j.ad.2010.10.01621377137Search in Google Scholar

14. Biobadaser.ser.es [Internet], Spain: Fundacion Academia Espanola de Dermatologia. Protocol registration receipt; 2013 [cited 2014 Feb 4]. Available from: https://biobadaser.ser.es/biobadaderm/cgi-bin/upload/archivo.aspx?id=21.Search in Google Scholar

15. Augustin M, Spehr C, Radtke M, Boehncke W, Luger T, Mrowietz U, Reusch M, Stromer K, Wozel G, Kiedrowski R, Rustenbach S, Purwins S, Reich K. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges 2014; 12 (1): 48-57.10.1111/ddg.1223324393314Search in Google Scholar

16. Arenberger P. Zápis ze schúze výboru ČDS konané dne 1. dubna 2010 v Praze. Česká a slovenská dermatovenerologie 2010; 85 (4): 241-2.Search in Google Scholar

17. Dermanet.cz [Internet], Czech Republic: Česká akademie dermatovenerologie - Centra biologické léčby; [updated 2013; cited 2014 Feb 5]. Available from: http://www.dermanet.cz/cs/kozni-ordinace/centra-biologicke-lecby/.Search in Google Scholar

18. Ordinace.cz [Internet], Czech Republic: Vyšínová R. „Nejsme spokojeni s výsledky léčby,“ říkají pacienti s lupénkou; 4 6 2012 [updated 2012 Jun 4; cited 2014 Feb 5]. Available from: http://www.ordinace.cz/clanek/nejsme-spokojeni-rikaji-pacienti-s-lupenkou/?chapter=1.Search in Google Scholar

19. Prolekare.cz [Internet], Czech Republic: Arenberger P. Česko-slovenská dermatologie; [updated 2011 Jan; cited 2014 Feb 5]. Available from: web.lfhk.cuni.cz/dermat/data/zapis_13_01_2011.doc.Search in Google Scholar

20. Clinicaltrials.gov [Internet], United States: Swiss Dermatology Network for Targeted Therapies; [updated 2012 Oct 12; cited 2014 Feb 5]. Available from: http://clinicaltrials.gov/show/NCT01706692.Search in Google Scholar

21. Clinicaltrials.gov [Internet], United States: Assistance Publique - Hôpitaux de Paris; Study record detail; [updated 2012 Jun 8; cited 2014 Feb 5]. Available from: http://clinicaltrials.gov/show/NCT01617018.Search in Google Scholar

22. Ormerod A, Augustin M, Baker C, Chosidow O, Cohen A, Dam T, Garcia-Doval I, Lecluse L, Schmitt-Egenolf M, Spuls P, Watson K, Naldi L. Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies. Dermatology 2012; 224: 236-43.10.1159/00033857222678413Search in Google Scholar

23. Meduni-graz.at [Internet], Austria: Medizinische Universität Graz; Bioimmuntherapie: Register & Datenbanken; [updated 2013; cited 2014 Feb 6]. Available from: http://www.medunigraz.at/13818.Search in Google Scholar

24. Cohen A, Weitzman D, Dreiher J. Psoriasis and Hypertension: A Case-Control Study. Acta Derm Venereol 2010; 90: 23-6.10.2340/00015555-074120107721Search in Google Scholar

25. Psoriasis.asn.au [Internet], Australia: Australasian psoriasis registry; [updated 2008; cited 2015 Feb 12]. Available from: https://www.psoriasis.asn.au/default.aspx?Logout=Refresh.Search in Google Scholar

26. Chang C, Gangaram H, Hussein S. Malaysian Psoriasis Registry - preliminary report of a pilot study using a newly revised registry form. Med J Malaysian 2008; 63: 68-71.Search in Google Scholar

27. Acrm.org.my [Internet], Malaysia: Mohd Affandi A, Alias F, Johar A, Baba R. Annual Report of the Malaysian Psoriasis Registry 2007-2012; [updated 2014; cited 2015 Feb 12]. Available from: http://www.acrm.org.my/dermreg/documents/MPR_Annual_Report_2007-2012_Final.pdfSearch in Google Scholar

28. Psoriasis.org [Internet], United States: National psoriasis foundation; [updated 2014 Jan 8; cited 2014 Feb 6]. Available from: http://www.psoriasis.org/news/press-releases/2014/01/08/npfand-coronna-co-develop-first-nonprofit-psoriasis-registry.Search in Google Scholar

29. Clinicaltrials.gov [Internet], United States: Centocor Ortho Biotech Services, L.L.C.; [updated 2014 Jan 16; cited 2014 Feb 6]. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00508547?term=psolar&rank=1.Search in Google Scholar

30. Papp K., Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012; 11 (10): 1210-7.Search in Google Scholar

31. Gliklich R, Bertagna M. The emerging role of the patient registry. Good Clinical Practice journal 2006; 14-7.Search in Google Scholar

32. Gliklich R, Dreyer N, Registries for evaluating patient outcomes: User s guide, 2 ed. Rockville: Agency for Healthcare Research and quality; 2010.Search in Google Scholar

33. Norlin J, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol 2012; 165(4): 797-802.10.1111/j.1365-2133.2011.10778.x22182212Search in Google Scholar

34. Blom C, Beikert F, Rustenbach S, Augustin M. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Arch Dermatol Res 2013; 305 (3): 197-204.10.1007/s00403-012-1309-223266843Search in Google Scholar

35. Shikiar R, Willian N, Okun M, Thompson C, Revicki D. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006; 4 (71): 1-12.10.1186/1477-7525-4-71161586917005043Search in Google Scholar

36. Nast A, Boehncke W, Mrowietz U, Ockenfels H, Philipp S. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG 2012; 10 (2): 51-595.Search in Google Scholar

37. Icmje.org [Internet], United States: International committee of Medical journal editor; [updated 2013 Dec; cited 2014 Feb 9]. Available from: http://www.icmje.org/icmje-recommendations.pdf.Search in Google Scholar

38. Meddra.org [Internet], United States: International conference on harmnisation; [updated 2013 Sep; cited 2014 Feb 14]. Available from: http://www.meddra.org/.Search in Google Scholar

39. Flytstrom I, Stenberg B, Svenson A, Bergbrant I. Patients’ Visual Analogue Scale: A Useful Method for Assessing Psoriasis Severity. Acta Derm Venereol 2012; 92: 339-409.10.2340/00015555-123722101827Search in Google Scholar

40. Hjortsberg C, Bergman A, Bjarnason A, Heikkilä H, Hjelmgren J, Svensson A, Tennvall G. Are treatment satisfaction, quality of life, and self-assessed disease severity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis. Acta Derm Venereol 2011; 91 (4): 409-14.10.2340/00015555-109421461549Search in Google Scholar

41. McInnes I, Combe B, Burmester G. Understanding the patient perspective - results of the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) patient needs survey. Clin Exp Rheumatol 2013; 31 (3): 350-57.Search in Google Scholar

42. Dougados M, Nataf H, Steinberg G, Rouanet S, Falissard B. Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. Rheumatology (Oxford) 2013; 52 (2): 391-9.10.1093/rheumatology/kes28523104976Search in Google Scholar

43. Finlay A, Basra M. DLQI and CDLQI scores should not be combined. Br J Dermatol 2012; 167 (2): 453-4.10.1111/j.1365-2133.2012.10922.x22385016Search in Google Scholar

44. Attra.registry.cz [Internet], Czech Republic: Česká revmatologická společnost - ATTRA clinical register; [updated 2014; cited 2014 Feb 26]. Available from: http://attra.registry.cz/.Search in Google Scholar

45. Iba. muni.cz [Internet], Czech republic: IBA Masarykova univerzita; [updated 2013; cited 2014 Feb 26]. Available from: http://www.iba.muni.cz/index.php?pg=vyzkum.Search in Google Scholar

46. Weller R. U.S. experience of immunomodulators in the treatment of psoriasis. Br J Dermatol 2005; 152 (4): 817-818; author reply 818-819.10.1111/j.1365-2133.2005.06495.x15840131Search in Google Scholar

47. Norlin J, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology 2012; 225 (4): 326-32.10.1159/00034571523328678Search in Google Scholar

48. Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Piaserico A, Naldi L. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry. J Am Acad Dermatol 2014; 70 (2): 257-62; e3. doi: 10.1016/j.jaad.2013.10.019.10.1016/j.jaad.2013.10.01924355410Search in Google Scholar

49. Garcia-Doval I, Rustenbach S, Stern R, Dam T, Cohen A, Baker C, Spuls P, Naldi L. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Br J Dermatol 2013; 169 (3): 710-4.10.1111/bjd.1234423551034Search in Google Scholar

50. SDS-sk.sk [Internet], Slovak Republic: Slovenská dermatovenerologická spoločnosť - Zápisnice zo zasadnutia výboru Slovenskej dermatovenerologickej spoločnosti - rok 2008; [updated 2008 Mar 14; cited 2014 Mar 16]. Available from: http://www.sds-sk.sk/2008.htm.Search in Google Scholar

51. SDS-sk.sk [Internet], Slovak Republic: Slovenská dermatovenerologická spoločnosť - Zápisnice zo zasadnutia výboru Slovenskej dermatovenerologickej spoločnosti - rok 2011; [updated 2011 May 20; cited 2014 Mar 16]. Available from: http://www.sds-sk.sk/2011_05_20%20Zapisni-ca%20zo%20zasadnutia%20vyboru%20SDVS%20Martin.pdf.Search in Google Scholar

52. Péč J, Palotai T, Šimaljaková M, Zaujec L, Polák I, Psotová M, Vrtíková E, Šalkovská J, Hemza M, Vojtáš I, Urbanček S, Ševc J, Chríbiková I, Martinásková K jr, Péčová K jr, Tindirová M, Martinásková K, Surňáková K, Jautová J, Baloghová J, Linkeschová E. Epidemiologická štúdia psoriázy v skupine biologicky naivných pacientov v podmienkach Slovenska. Biologická léčba 2011; 4 (1): 15-22.Search in Google Scholar

53. ICH Expert Working Group. GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R1) Current Step 4 version. Rockville: U.S. Department of Health and Human Services; 1996.Search in Google Scholar

54. Ezdravotnictvo.sk [Internet], Slovak Republic: Národné centrum zdravotníckych informácií; [updated 2011; cited 2014 Mar 6]. Available from: http://www.ezdravotnictvo.sk/Elektronicke-zdravotnictvo/Stranky/default.aspx.Search in Google Scholar

55. Sonnenreich P. Advances in psoriasis treatment: experts comment on recent developments. P T 2013; 38 (12): 776-9.Search in Google Scholar

56. Levy L, Solomon S, Emer J. Biologics in the treatment of psoriasis and emerging new therapies in the pipeline. Dove Press Journal: Psoriasis: Targets and Therapy 2012; 29-43.10.2147/PTT.S23860Search in Google Scholar

57. Ryan C, Korman N, Gelfand J, Lim H, Elmets C, Feldman S, Gottlieb A, Koo J, Lebwohl M, Leonardi C, Van Voorhees A, Bhushan R, Menter A. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol 2014; 70 (1): 146-67.10.1016/j.jaad.2013.08.04224126079Search in Google Scholar

58. Ahn C, Gustafson C, Sandoval L, Davis S, Feldman S. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol 2013; 14 (4): 315-26.10.1007/s40257-013-0030-z23696234Search in Google Scholar

59. Tan X, Feldman S, Balkrishnan R. Quality of life issues and measurement in patients with psoriasis. Psoriasis: Targets and Therapy 2012; 2: 13-23.Search in Google Scholar